Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
May 8, 2024 4:05 PM EDT- First quarter NUPLAZID® (pimavanserin) net product sales of $129.9 million
- First quarter DAYBUE (trofinetide) net product sales of $75.9 million
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.
In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% revenue growth year over year, primarily due to the addition of our second commercial product, DAYBUE for the treatment of Rett syndrome, combined with growth in market share of NUPLAZID for the... More
